Transient sub-cytotoxic lurbinectedin pre-treatment exploits the transcription-addiction architecture of reactive str...

IF a transient, sub-cytotoxic pulse of lurbinectedin (10 nM, 6-hour exposure followed by complete washout) is delivered to reactive striatal astrocytes isolated from 6-OHDA-lesioned C57BL/6 male mice (7 days post-lesion), followed 24 hours later by AAV9-hGFAP-NeuroD1 transduction at MOI 1×10⁵,

THEN the percentage of TH-positive dopaminergic neurons among total converted cells at day 21 post-transduction will be increased by ≥1.5-fold compared to AAV9-hGFAP-NeuroD1 transduction alone (from an estimated baseline of ~10–15% TH+ yield to ≥18–22%), as measured by automated confocal imaging across ≥6 fields per well with n=8 mice per group,

BECAUSE the following mechanistic chain is predicted to operate:

1. Lurbinectedin covalently binds CG-rich sequences (CG triplets) at CpG islands located downstream of the transcription start sites of actively transcribed astrocyte identity genes (GFAP, Aldh1l1, Sox9, Nfia), whose promoters are maintained in a steadily open chromatin environment and are enriched for RNAPII occupancy — a state documented for ASCL1/NEUROD1-driven gene networks in which transcriptional addiction renders cells disproportionately vulnerable to RNAPII disruption. (Costanzo et al. 2022, lurbinectedin arrests elongating RNAPII and promotes its degradation specifically at CpG-island-containing promoters of ASCL1/NEUROD1-regulated genes)[https://pubmed.ncbi.nlm.nih.gov/35263037/]

2. RNAPII stalling at astrocyte identity gene promoters triggers ubiquitin-proteasomal degradation of the RPB1 catalytic subunit, reducing the transcriptional output of master astrocyte identity regulators for a transient 24–72 hour window. Because reactive astrocytes in the 6-OHDA striatum upregulate GFAP, vimentin, and Sox9 under the same type of transcription-addicted, open-chromatin super-enhancer architecture that lurbinectedin exploits in SCLC neuroendocrine subtypes, the drug's mechanism is predicted to transfer functionally to this non-cancer cell context. (Lurbinectedin preferentially abrogates expression of ASCL1/NEUROD1 and their dependent gene networks, exploiting "transcription addiction" as an Achilles heel)[https://pubmed.ncbi.nlm.nih.gov/35263037/]

3. Physical eviction of stalled, ubiquitinated RNAPII from astrocyte identity gene promoters and the drug-induced minor-groove distortion transiently remodel local chromatin architecture, reducing nucleosome occupancy and histone mark density (H3K27Ac) at astrocytic loci. ATAC-seq datasets GSE179074 and GSE195663 from lurbinectedin-treated SCLC cells provide preliminary evidence that the drug induces alterations in chromatin accessibility profiles that are detectable within 24–72 hours of exposure and persist into the post-washout recovery phase. (GSE179074 and GSE195663 chromatin profiling data demonstrate lurbinectedin-induced redistribution of chromatin accessibility)[https://pubmed.ncbi.nlm.nih.gov/35263037/]

4. **During the 24–96 hour post-washout window — before astrocyte ide...

SENS category: RepleniSENS